Dan L Zimbroff

Summary

Publications

  1. ncbi request reprint Best clinical practice with ziprasidone IM: update after 2 years of experience
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, California 91786, USA
    CNS Spectr 10:1-15. 2005
  2. ncbi request reprint Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, CA 91786, USA
    J Clin Psychopharmacol 27:171-6. 2007
  3. ncbi request reprint Pharmacological control of acute agitation: focus on intramuscular preparations
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, California, USA
    CNS Drugs 22:199-212. 2008
  4. ncbi request reprint Management of acute psychosis: from emergency to stabilization
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, San Bernardino, California, USA
    CNS Spectr 8:10-5. 2003
  5. ncbi request reprint Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations
    David G Daniel
    United BioSource Corporation, McLean, VA 22106, USA
    J Psychiatr Pract 13:170-7. 2007
  6. ncbi request reprint Intramuscular aripiprazole in the control of agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Psychiatr Pract 13:159-69. 2007
  7. ncbi request reprint Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
  8. ncbi request reprint The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy
    David G Daniel
    Bioniche Development Inc, McLean, Virginia, USA
    Int Clin Psychopharmacol 19:9-15. 2004
  9. ncbi request reprint Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    John M Kane
    Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 63:763-71. 2002
  10. ncbi request reprint Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003

Detail Information

Publications10

  1. ncbi request reprint Best clinical practice with ziprasidone IM: update after 2 years of experience
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, California 91786, USA
    CNS Spectr 10:1-15. 2005
    ..Additional trials of ziprasidone IM in agitated patients in a variety of clinical setting are warranted to generate comparative risk/benefit data with conventional agents and other second-generation antipsychotics...
  2. ncbi request reprint Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, CA 91786, USA
    J Clin Psychopharmacol 27:171-6. 2007
    ..3%) and IM lorazepam (19.1%). IM aripiprazole 9.75 and 15 mg are effective and well tolerated for acute agitation in bipolar disorder, although the low incidence of oversedation suggests a risk-benefit profile for IM aripiprazole 9.75 mg...
  3. ncbi request reprint Pharmacological control of acute agitation: focus on intramuscular preparations
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, Upland, California, USA
    CNS Drugs 22:199-212. 2008
    ....
  4. ncbi request reprint Management of acute psychosis: from emergency to stabilization
    Dan L Zimbroff
    Pacific Clinical Research Medical Group, San Bernardino, California, USA
    CNS Spectr 8:10-5. 2003
    ..This article will review the use of intramuscular agents, standard antipsychotics, and new antipsychotics in the emergency room setting. The strengths and limitations of each will be discussed...
  5. ncbi request reprint Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations
    David G Daniel
    United BioSource Corporation, McLean, VA 22106, USA
    J Psychiatr Pract 13:170-7. 2007
    ..To report efficacy and safety of transitioning patients receiving intramuscular (IM) formulations of aripiprazole or haloperidol to their respective oral formulations...
  6. ncbi request reprint Intramuscular aripiprazole in the control of agitation
    Glenn W Currier
    Department of Psychiatry, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Psychiatr Pract 13:159-69. 2007
    ..To evaluate response to intramuscular (IM) aripiprazole injections using secondary analyses from clinical trials...
  7. ncbi request reprint Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial
    Alan D Feiger
    Department of Psychiatry, University of Colorado School of Medicine, Denver, CO, USA
    J Clin Psychiatry 67:1354-61. 2006
    ..This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD)...
  8. ncbi request reprint The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy
    David G Daniel
    Bioniche Development Inc, McLean, Virginia, USA
    Int Clin Psychopharmacol 19:9-15. 2004
    ..Ziprasidone i.m. 5,10, and 20 mg qid, given for 3 days were well tolerated. The transition from i.m. to oral ziprasidone was well tolerated with continuing maintenance of symptom control...
  9. ncbi request reprint Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder
    John M Kane
    Zucker Hillside Hospital, Glen Oaks, NY, USA
    J Clin Psychiatry 63:763-71. 2002
    ..Aripiprazole is an investigational agent for treating schizophrenia that has a novel pharmacologic profile. The present study investigated the efficacy, safety, and tolerability of aripiprazole and haloperidol compared with placebo...
  10. ncbi request reprint Pregabalin in generalized anxiety disorder: a placebo-controlled trial
    Atul C Pande
    Pfizer Global Research and Development, Ann Arbor Laboratories, MI, USA
    Am J Psychiatry 160:533-40. 2003
    ..Current drug therapies for generalized anxiety disorder have limitations. In a controlled trial, the novel agent pregabalin was studied for the treatment of patients with generalized anxiety disorder...